News
-
-
-
-
-
-
PRESS RELEASE
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
Jaguar announces compassionate use of crofelemer in EU for infant with IF due to MVID. Ongoing trials show promising results in reducing PS in pediatric patients for over a year -
-
-
PRESS RELEASE
Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Under Review
First Berlin Equity Research updates rating and price target for Jaguar Health Inc (ISIN: US47010C8055) to 'Under Review' due to recent restructuring steps and ongoing liquidity concerns, while recognizing positive clinical developments -
